Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:FATE), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 6.0% to $6.11. Recent analyst actions include both upgrades and downgrades, reflecting mixed sentiments about the company's future performance.
June 17, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on Fate Therapeutics, with recent ratings showing both upgrades and downgrades. The average 12-month price target has decreased by 6.0% to $6.11, indicating a cautious outlook.
The mixed analyst ratings and the decrease in the average price target suggest a cautious outlook for Fate Therapeutics. While some analysts have upgraded their ratings, others have downgraded, reflecting uncertainty about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100